IFM Investors Pty Ltd Increases Stock Position in Edwards Lifesciences Co. (NYSE:EW)

IFM Investors Pty Ltd grew its position in Edwards Lifesciences Co. (NYSE:EWGet Rating) by 5.0% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 107,644 shares of the medical research company’s stock after purchasing an additional 5,084 shares during the period. IFM Investors Pty Ltd’s holdings in Edwards Lifesciences were worth $10,236,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in EW. Clark Capital Management Group Inc. increased its holdings in Edwards Lifesciences by 65.4% during the fourth quarter. Clark Capital Management Group Inc. now owns 3,524 shares of the medical research company’s stock worth $457,000 after buying an additional 1,393 shares during the last quarter. Quantitative Investment Management LLC purchased a new position in shares of Edwards Lifesciences in the fourth quarter worth about $1,335,000. Nuveen Asset Management LLC increased its stake in shares of Edwards Lifesciences by 53.5% in the fourth quarter. Nuveen Asset Management LLC now owns 4,401,030 shares of the medical research company’s stock worth $570,153,000 after purchasing an additional 1,533,795 shares in the last quarter. ETF Managers Group LLC increased its stake in shares of Edwards Lifesciences by 5.0% in the fourth quarter. ETF Managers Group LLC now owns 8,167 shares of the medical research company’s stock worth $1,067,000 after purchasing an additional 387 shares in the last quarter. Finally, IHT Wealth Management LLC increased its stake in shares of Edwards Lifesciences by 53.6% in the fourth quarter. IHT Wealth Management LLC now owns 7,779 shares of the medical research company’s stock worth $1,008,000 after purchasing an additional 2,715 shares in the last quarter. Hedge funds and other institutional investors own 81.33% of the company’s stock.

Insider Buying and Selling

In related news, VP Larry L. Wood sold 7,242 shares of the company’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $95.90, for a total value of $694,507.80. Following the transaction, the vice president now owns 202,232 shares in the company, valued at approximately $19,394,048.80. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Edwards Lifesciences news, VP Larry L. Wood sold 7,242 shares of the company’s stock in a transaction dated Tuesday, July 5th. The shares were sold at an average price of $95.90, for a total transaction of $694,507.80. Following the transaction, the vice president now owns 202,232 shares in the company, valued at approximately $19,394,048.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Michael A. Mussallem sold 19,875 shares of the company’s stock in a transaction dated Thursday, September 22nd. The shares were sold at an average price of $84.17, for a total transaction of $1,672,878.75. Following the transaction, the chief executive officer now owns 157,353 shares in the company, valued at approximately $13,244,402.01. The disclosure for this sale can be found here. Insiders have sold a total of 86,128 shares of company stock worth $8,223,839 in the last quarter. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently weighed in on the stock. Canaccord Genuity Group downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating and reduced their target price for the stock from $115.00 to $106.00 in a research note on Friday, July 29th. Cowen cut their price objective on shares of Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Cowen cut their price objective on shares of Edwards Lifesciences from $140.00 to $125.00 in a research report on Monday, July 11th. Morgan Stanley cut their price objective on shares of Edwards Lifesciences from $136.00 to $119.00 and set an “overweight” rating for the company in a research report on Friday, July 15th. Finally, StockNews.com upgraded shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Wednesday, August 17th. Three investment analysts have rated the stock with a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Edwards Lifesciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $125.81.

Edwards Lifesciences Stock Performance

Shares of EW stock opened at $84.17 on Friday. Edwards Lifesciences Co. has a 12 month low of $83.42 and a 12 month high of $131.73. The stock has a market cap of $52.18 billion, a PE ratio of 36.44, a price-to-earnings-growth ratio of 2.52 and a beta of 1.14. The company has a current ratio of 3.37, a quick ratio of 2.60 and a debt-to-equity ratio of 0.10. The company’s fifty day moving average price is $97.39 and its 200-day moving average price is $101.83.

Edwards Lifesciences (NYSE:EWGet Rating) last announced its quarterly earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.64 by ($0.01). The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.40 billion. Edwards Lifesciences had a return on equity of 24.77% and a net margin of 27.18%. The business’s revenue for the quarter was down .2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.64 EPS. On average, equities analysts expect that Edwards Lifesciences Co. will post 2.51 EPS for the current fiscal year.

About Edwards Lifesciences

(Get Rating)

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases.

Read More

Institutional Ownership by Quarter for Edwards Lifesciences (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.